TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
Johnson & Johnson reported positive topline results from the Phase 3 MonumenTAL-6 study, showing that the TECVAYLI + TALVEY regimen reduced the risk of disease progression or death by 89% (HR 0.11) in earlier-line relapsed/refractory multiple myeloma. The study also met its primary endpoint for the TALVEY plus pomalidomide arm, which reduced the risk of progression or death by 73% compared to standard of care.
Key figures
- Drug Name
- TECVAYLI® (teclistamab-cqyv) + TALVEY® (talquetamab-tgvs)
- Phase Of Trial
- Phase 3
- P value tec tal
- <0.0001
- Pfs hazard ratio tal p
- 0.27
- Os hazard ratio tec tal
- 0.38
- Pfs hazard ratio tec tal
- 0.11
- Pfs risk reduction tal p
- 73%
- Os risk reduction tec tal
- 62%
- Pfs risk reduction tec tal
- 89%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.